Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is a single-center phase Ⅱ study designed to evaluated the efficacy and safety of
pegylated liposomal doxorubicin（PLD）in combination with trastuzumab in HER-2 positive
metastatic breast cancer .